Announcements

Refer to the Medical Repricing page for more information.

Prior to 28 October 2019, the underlying master fund of Manulife Emerging Eastern Europe Fund, namely Manulife Global Fund-Emerging Eastern Europe Fund (MGF-EEEF) charges Annual Performance Fee, which will only be applicable when the Net Asset Value exceeds the Target Net Asset Value for the particular financial year ('Excess'). The Annual Performance Fee is equivalent to 8% of the Excess.

For the benefits of policyowners, this Annual Performance Fee is removed effective 28 October 2019

Refer to the Frequently Asked Question (FAQ) for more information.

With effect from 15 April 2019, Interim Cover will be provided, subject to the Terms and Conditions 

With effect from 24 Jan 2019, the List of Covered Events has been extended to include the following critical illnesses:

1. Occupationally Acquired HIV Infection
   
2. Brain Surgery
   
3. Terminal Illness
    

List of eligible products are as follows:

1. Critical Illness Protect
   
2. AdvanceCare
   
3. Premium Protect
   
4. Payor Income
   
5. Payor Waiver
   
6. CI Waiver
   
7. Waiver of Premium Benefit
   
8. Elite Credit Shield*
    

 *Only Occupationally Acquired HIV Infection and Brain Surgery will be included,  where the current Elite Credit Shield already covers Terminal Illness.

This extension shall also apply retrospectively to existing policy issued from 1 Jan 2015 onwards. The standard 30 days Waiting Period and Pre-Existing Condition clause shall be applicable.

Premium rates/insurance charges, all other features and benefits, as well as terms and conditions of the eligible products shall remain unchanged.

With effect from 9 Jan 2019, the List of Covered Events has been extended to include the following critical illnesses:

1. Occupationally Acquired HIV Infection
2. Brain Surgery
3. Terminal Illness
    

List of eligible products are as follows:

1. Accelerated CI
2. Additional CI
3. CI Early Advantage Benefit
4. Waiver of Premium Benefit
5. Manulife Cover-Me-Again Benefit
6. Premium Care Benefit
7. CI Income Plus Benefit
8. Payor IncomeLink Benefit
9. Spouse IncomeLink Benefit
10. ManuLife Cover-Me-Again
11. Critical Illness Rider
12. CI Income Rider
13. Payor Plus Income Rider
14. Accelerated CI with IPB
15. CI IncomeLink Benefit
16. CI Early Advantage
17. CI Early Advantage Rider
     

This extension shall also apply retrospectively to existing policy issued from 1 Jan 2015 onwards. The standard 30 days Waiting Period and Pre-Existing Condition clause shall be applicable.

Premium rates/insurance charges, all other features and benefits, as well as terms and conditions of the eligible products shall remain unchanged. 

With effect from 18 May 2018, the "Upgraded Room and Board Co Payment" clause will be removed for MedCare Plus 2 attachable to Elite Smart Life, Elite Smart Kids and Elite Prime Life. This removal shall be applied retrospectively to existing MedCare Plus 2 Policy owner.

Insurance charges, all other features and benefits, as well as the Terms and Conditions of MedCare Plus 2 shall remain unchanged. For any question on the removal of Upgraded Room and Board Co-Payment, please contact your authorised bank representative or refer to the Frequently Asked Question (FAQ) for more information.

With effect from 5-January-2018, the ‘Upgraded Room and Board Co-Payment” will be removed for the medical products listed below retrospectively:

1. ManuMedic
2. ManuMedic+
3. ManuMedic Link
4. ManuMedic Link+

Insurance charges, all other features and benefits, as well as the Terms and Conditions of the products listed above shall remain unchanged. For any question on the removal of Upgraded Room and Board Co-Payment, please contact your servicing agent or refer to the Frequently Asked Question (FAQ) for more information.

The Corporate Outsource Services Sdn Bhd (COSSB) hotline number for hospital admissions will be changed to 1300 88 0100 with effect from 31 December 2017.

Effective 15 November 2017, the target fund for Manulife China Value Fund will be changed from Manulife Global Fund-China Value Fund (MGF-CVF) to Manulife Investment-Greater China Fund (MI-GCF) 

Refer to the Frequently Asked Question (FAQ) for more information.

Notification of Revision to the Investment Objectives of the SIP Aggressive Portfolio, SIP Growth Portfolio and SIP Balanced Portfolio

Effective 1 December 2018, the Investment Objective of SIP Aggressive Portfolio, SIP Growth Portfolio and SIP Balanced Portfolio will be replaced as follows and such change will not result in changes in the investment objective and strategy of the Fund:

Investment Objectives

1. SIP Aggressive Portfolio is a unitized fund of the plan, which is designed to provide long-term capital growth. It is designed for those who hold a long-term investment view and who are prepared to accept significant fluctuations in the value of their investments in order to achieve long-term returns. It is intended that the investments will be made on a diversified basis. Around eighty percent (80%) of its underlying investment portfolio will consist of equities and equity-related investments, with the remainder of the assets being directly or indirectly invested in bonds, deposits and other investments. The intended target asset allocation as mentioned above is for reference only.
   
   
2. SIP Growth Portfolio is a unitized fund of the Plan which is designed to provide medium to long term capital growth for those who hold a long term investment view and who are prepared to accept considerable fluctuations in the value of their investments in order to achieve long term returns. It is intended that the investments will be made on a diversified basis. Around sixty percent (60%) of its underlying investment portfolio will consist of equities and equity-related investments, with the remainder of the assets being directly or indirectly invested in bonds, deposits and other investments. The intended target asset allocation as mentioned above is for reference only.
   
   
3. SIP Balanced Portfolio is a unitized fund of the Plan which is designed to provide medium to long term capital growth for those who hold a long term investment view and who are prepared to accept fluctuations in the value of their investments in order to achieve long term returns. It is intended that the investments will be made on a diversified basis. Around forty percent (40%) of its underlying investment portfolio will consist of equities and equity-related investments, with the remainder of the assets being directly or indirectly invested in bonds, deposits and other investments. The intended target asset allocation as mentioned above is for reference only.

The Underlying Funds (including its fund manager) and asset allocations may be changed as and when the Company deems appropriate, provided it is in line with the Fund's investment objective and strategy.